This company has been acquired
Sigilon Therapeutics Past Earnings Performance
Past criteria checks 0/6
Sigilon Therapeutics's earnings have been declining at an average annual rate of -3.5%, while the Biotechs industry saw earnings growing at 25.3% annually. Revenues have been growing at an average rate of 4.7% per year.
Key information
-3.5%
Earnings growth rate
54.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 4.7% |
| Return on equity | -110.2% |
| Net Margin | -171.3% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Benign Growth For Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Underpins Stock's 34% Plummet
Apr 17
Sigilon Therapeutics GAAP EPS of -$0.44, revenue of $2.88M
Aug 04Sigilon Therapeutics names Philip Ashton-Rickardt as chief scientific officer
Jun 14What Percentage Of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Shares Do Insiders Own?
Mar 04Sigilon Therapeutics' MPS-1 gene therapy an Orphan Drug in U.S.
Dec 17Revenue & Expenses BreakdownBeta
How Sigilon Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 18 | -30 | 19 | 0 |
| 31 Mar 23 | 15 | -37 | 18 | 0 |
| 31 Dec 22 | 13 | -44 | 19 | 0 |
| 30 Sep 22 | 12 | -55 | 19 | 0 |
| 30 Jun 22 | 10 | -66 | 20 | 0 |
| 31 Mar 22 | 10 | -72 | 20 | 0 |
| 31 Dec 21 | 10 | -77 | 20 | 0 |
| 30 Sep 21 | 11 | -75 | 19 | 0 |
| 30 Jun 21 | 14 | -68 | 17 | 0 |
| 31 Mar 21 | 13 | -61 | 15 | 0 |
| 31 Dec 20 | 13 | -55 | 13 | 0 |
| 30 Sep 20 | 13 | -52 | 12 | 0 |
| 30 Jun 20 | 13 | -51 | 11 | 0 |
| 31 Mar 20 | 14 | -47 | 11 | 0 |
| 31 Dec 19 | 14 | -44 | 10 | 0 |
| 31 Dec 18 | 5 | -26 | 7 | 0 |
Quality Earnings: SGTX is currently unprofitable.
Growing Profit Margin: SGTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SGTX is unprofitable, and losses have increased over the past 5 years at a rate of 3.5% per year.
Accelerating Growth: Unable to compare SGTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SGTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-31.3%).
Return on Equity
High ROE: SGTX has a negative Return on Equity (-110.18%), as it is currently unprofitable.